Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
Start Date
3/14/2022
Completion Date
7/1/2027
Summary
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiments done in the laboratory. These experiments may help researchers understand how cancer cells manage their nutrients when compared to normal pancreatic cells.
Detailed Description
PRIMARY OBJECTIVE: I. To describe and discover new insights into the glucose, tricarboxylic acid (TCA) cycle, amino acid, and lipid metabolic dependencies of pancreatic ductal adenocarcinoma (PDAC) via liquid chromatography-mass spectrometry (LC-MS) analysis of in vivo uniformly-labeled \[13C\]glucose (U-13C-glucose) labeled pancreatic cancer biopsies. OUTLINE: Patients receive uniformly-labeled \[13C\]glucose intravenously (IV) over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Biopsy
Therapeutic Conventional Surgery
Uniformly-labeled [13C]glucose
Conditions
Locations
Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)
Livingston, New Jersey 07039
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08903
United States